Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 7/20 | 0.83 |
| ▸ | NADK | O95544 | 1/20 | 0.83 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.74 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | PNMT | P11086 | 1/20 | 0.74 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.74 |
| ▸ | DPP4 | P27487 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.74 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.74 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.74 |
| ▸ | GAPDH | P04406 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.74 |
| ▸ | STAT6 | P42226 | 1/20 | 0.74 |
| ▸ | PI4KA | P42356 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylthioadenosine SCHEMBL29439558 | 1.00 | AHCY (0.83) | AHCYNADKDOT1LDNMT3BADORA3 | |
| Methylthioadenosine SCHEMBL20798030 | 1.00 | AHCY (0.83) | AHCYNADKDOT1LDNMT3BADORA3 | |
| Methylthioadenosine SCHEMBL160358 | 1.00 | AHCY (0.83) | AHCYNADKDOT1LDNMT3BADORA3 | |
| Methylthioadenosine SCHEMBL29361072 | 1.00 | AHCY (0.83) | AHCYNADKDOT1LDNMT3BADORA3 | |
| Methylthioadenosine SCHEMBL31388809 | 1.00 | AHCY (0.83) | AHCYNADKDOT1LDNMT3BADORA3 | |
| Methylthioadenosine SCHEMBL11954365 | 1.00 | AHCY (0.83) | AHCYNADKDOT1LDNMT3BADORA3 | |
| Methylthioadenosine SCHEMBL10013421 | 1.00 | AHCY (0.83) | AHCYNADKDOT1LDNMT3BADORA3 | |
| Methylthioadenosine SCHEMBL101382 | 1.00 | AHCY (0.83) | AHCYNADKDOT1LDNMT3BADORA3 | |
| Methylthioadenosine SCHEMBL7124285 | 0.95 | DOT1L (0.78) | AHCYNADKDOT1LDNMT3BPNMT | |
| Methylthioadenosine SCHEMBL20817193 | 0.91 | AHCY (0.70) | AHCYNADKDOT1LDNMT3BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102573854-A | 5'-methylthioadenosine neuroprotective properties | PROYECTO BIOMEDICINA CIMA SL | 2012-07-11 | — | — | CN | claimed |
| CN-101141970-A | Use of 5' -Methylthioadenosine (MTA) for the prevention and/or treatment of autoimmune diseases and/or transplant rejection | SIMA BIOLOG MEDICAL INFORMATIO (ES) | 2008-03-12 | — | — | CN | claimed |
| CN-1395918-A | Usage of 5'-deoxidation-5'-methyl-sulphur-adenosin in cosmetic composition for skin | BASF AG (DE) | 2003-02-12 | — | — | CN | claimed |
| WO-2025085615-A1 | METHODS TO RAPIDLY DETECT METHYLTHIOADENOSINE AND RELATED METABOLITES DIRECTLY FROM PATIENT SAMPLES TO IDENTIFY 9P21 LOSS CANCERS AND TREATMENT STRATEGIES FOR PATIENTS | BAYLOR COLLEGE OF MEDICINE (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025085615-A1 | METHODS TO RAPIDLY DETECT METHYLTHIOADENOSINE AND RELATED METABOLITES DIRECTLY FROM PATIENT SAMPLES TO IDENTIFY 9P21 LOSS CANCERS AND TREATMENT STRATEGIES FOR PATIENTS | BAYLOR COLLEGE OF MEDICINE (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250060343-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC | 2025-02-20 | — | — | US | disclosed |
| US-12146869-B2 | Methods and compositions for analyte quantification | MATTERWORKS INC (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4437319-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | Matterworks Inc (US) | 2024-10-02 | — | — | EP | disclosed |
| US-12100484-B2 | Methods and compositions for analyte quantification | MATTERWORKS INC (MA) | 2024-09-24 | — | — | US | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240197729-A1 | ALK-5 Inhibitors and Uses Thereof | SUMITOMO PHARMA ONCOLOGY INC (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2009115634-A1 | SYNERGIC 5'-METHYLTHIOADENOSINE COMBINATIONS | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2009-09-24 | — | — | WO | disclosed |
| US-20090042831-A1 | USE OF 5'-METHYLTHIOADENOSINE (MTA) IN THE PREVENTION AND/OR TREATMENT OF AUTOIMMUNE DISEASES AND/OR TRANSPLANT REJECTION | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2009-02-12 | — | — | US | disclosed |
| US-20090042831-A1 | USE OF 5'-METHYLTHIOADENOSINE (MTA) IN THE PREVENTION AND/OR TREATMENT OF AUTOIMMUNE DISEASES AND/OR TRANSPLANT REJECTION | PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) | 2009-02-12 | — | — | US | disclosed |
| CN-1513997-A | Method of detecting 5'-methioadenosine phosphorylase defect type mammarian cell | ���������Ǵ�ѧ���»� | 2004-07-21 | — | — | CN | disclosed |
| CN-1103820-C | Method for detecting 5' -methylthioadenosine phosphorylase deficient mammalian cell | UNIV CALIFORNIA (US) | 2003-03-26 | — | — | CN | disclosed |
| CN-1395918-A | Usage of 5'-deoxidation-5'-methyl-sulphur-adenosin in cosmetic composition for skin | BASF AG (DE) | 2003-02-12 | — | — | CN | disclosed |
| CN-1145640-A | Method for detecting 5' -methylthioadenosine phosphorylase deficient mammalian cell | UNIV CALIFORNIA (US) | 1997-03-19 | — | — | CN | disclosed |
| CN-1013448-B | N6Process for producing-substituted deoxyriboadenosine analogues | WARNER LAMBERT CO (US) | 1991-08-07 | — | — | CN | disclosed |
| CN-85108658-A | N 6The manufacture method that replaces ribodesose adenyhomotype thing | — | 1986-07-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197729-A1 | ALK-5 Inhibitors and Uses Thereof | ACVR1, ALK, ACVRL1 | AHCY 1941/4885NADK 1677/4885DOT1L 2934/4885 |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | EGFR, ERBB2, ERBB3 | AHCY 1539/4885NADK 1893/4885DOT1L 2807/4885 |
| US-20090042831-A1 | USE OF 5'-METHYLTHIOADENOSINE (MTA) IN THE PREVENTION AND/OR TREATMENT OF AUTOIMMUNE DISEASES AND/OR TRANSPLANT REJECTION | TPMT, MTAP, MGMT | AHCY 7/4885NADK 2298/4885DOT1L 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.